Analysis of 40 studies reveals that GLP-1 receptor agonists like semaglutide and liraglutide cause significant dermatological changes beyond their intended metabolic effects. Users experience facial volume loss dubbed "Ozempic face," dermal thinning, collagen and elastin fiber breakdown, and decreased skin elasticity. These changes result from rapid subcutaneous fat loss that outpaces the skin's ability to adapt. The aesthetic implications challenge the straightforward narrative around these blockbuster medications. While GLP-1 drugs deliver impressive weight loss and diabetes control, they're essentially trading one health concern for another—premature skin aging that may require cosmetic intervention. Risk factors include older age, prolonged obesity history, and rapid weight loss, suggesting the skin changes aren't merely cosmetic but represent genuine tissue damage. This finding has profound implications for the millions using these medications, particularly younger users who may face decades of accelerated skin aging. The research highlights a critical knowledge gap in long-term aesthetic consequences of rapid pharmaceutical weight loss, contrasting sharply with gradual lifestyle-based approaches that allow skin adaptation.